All case study of Lenvima Capsule

Post-Marketing Surveillance of Lenvima Capsule in patients with unresectable thyroid cancer in Japan (All case study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080222856

Enrollment

400

Registered

2015-05-22

Start date

2015-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable thyroid cancer

Interventions

investigational material(s) Generic name etc : Lenvima Capsule4 mg, 10 mg INN of investigational material : Lenvatinib Mesilate Therapeutic category code : 429 Other antitumor agents Dosage and Admini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable thyroid cancer

Exclusion criteria

Exclusion criteria: 1)Corresponding to contraindication of Lenvima Capsule 2)Not applicable to indications of Lenvima Capsule

Design outcomes

Primary

Measure	Time frame
Safety All case study	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026